APA (7th ed.) Citation

Vermeire, S., D'Haens, G., Baert, F., Danese, S., Kobayashi, T., Loftus, E. V., . . . Sandborn, W. J. (2022). Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. Journal of Crohn's & Colitis, 16(1), 27. https://doi.org/10.1093/ecco-jcc/jjab133

Chicago Style (17th ed.) Citation

Vermeire, Séverine, et al. "Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial." Journal of Crohn's & Colitis 16, no. 1 (2022): 27. https://doi.org/10.1093/ecco-jcc/jjab133.

MLA (9th ed.) Citation

Vermeire, Séverine, et al. "Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial." Journal of Crohn's & Colitis, vol. 16, no. 1, 2022, p. 27, https://doi.org/10.1093/ecco-jcc/jjab133.